1,004
Participants
Start Date
November 28, 2022
Primary Completion Date
May 22, 2025
Study Completion Date
May 22, 2025
NgG low dose investigational vaccine
Two doses of NgG low dose investigational vaccine, administered intramuscularly.
NgG medium dose investigational vaccine
Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
NgG high dose investigational vaccine
Two doses of NgG high dose investigational vaccine, administered intramuscularly.
Placebo
Two doses of placebo, administered intramuscularly.
NgG HTD investigational vaccine
Two doses of NgG HTD investigational vaccine, administered intramuscularly.
NgG below HTD investigational vaccine
Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
GSK Investigational Site, Manila
GSK Investigational Site, Johannesburg
GSK Investigational Site, Soweto
GSK Investigational Site, The Bronx
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Hamburg
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Bochum
GSK Investigational Site, Valencia
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Frankfurt
GSK Investigational Site, Springfield
GSK Investigational Site, Lenexa
GSK Investigational Site, Lyon
GSK Investigational Site, Pierre-Bénite
GSK Investigational Site, Paris
GSK Investigational Site, Austin
GSK Investigational Site, Boston
GSK Investigational Site, Salvador
GSK Investigational Site, Barcelona
GSK Investigational Site, London
GSK Investigational Site, London
Lead Sponsor
GlaxoSmithKline
INDUSTRY